Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) has received an average rating of "Hold" from the nine analysts that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $19.50.
Several equities analysts have weighed in on ATRA shares. StockNews.com started coverage on Atara Biotherapeutics in a report on Wednesday, October 12th. They set a "hold" rating for the company. EF Hutton Acquisition Co. I initiated coverage on shares of Atara Biotherapeutics in a research note on Thursday, January 5th. They issued a "buy" rating and a $25.00 price target on the stock.
Get Atara Biotherapeutics alerts:Insider Buying and Selling at Atara Biotherapeutics
In other news, CFO Utpal Koppikar sold 6,255 shares of the company's stock in a transaction dated Wednesday, November 16th. The shares were sold at an average price of $4.49, for a total value of $28,084.95. Following the completion of the sale, the chief financial officer now directly owns 191,334 shares of the company's stock, valued at $859,089.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CFO Utpal Koppikar sold 6,255 shares of the stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $4.49, for a total value of $28,084.95. Following the sale, the chief financial officer now directly owns 191,334 shares in the company, valued at $859,089.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Pascal Touchon sold 15,591 shares of the stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $4.49, for a total transaction of $70,003.59. Following the completion of the sale, the chief executive officer now owns 441,696 shares in the company, valued at $1,983,215.04. The disclosure for this sale can be found here. Insiders sold 29,800 shares of company stock worth $133,802 over the last 90 days. Corporate insiders own 4.00% of the company's stock.
Hedge Funds Weigh In On Atara Biotherapeutics
Hedge funds have recently made changes to their positions in the stock. Nisa Investment Advisors LLC raised its stake in shares of Atara Biotherapeutics by 893.8% in the 3rd quarter. Nisa Investment Advisors LLC now owns 6,460 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 5,810 shares during the period. US Bancorp DE boosted its holdings in shares of Atara Biotherapeutics by 6,394.9% in the 3rd quarter. US Bancorp DE now owns 7,664 shares of the biotechnology company's stock valued at $29,000 after buying an additional 7,546 shares during the period. First Republic Investment Management Inc. acquired a new position in Atara Biotherapeutics during the 3rd quarter valued at about $38,000. Lazard Asset Management LLC acquired a new position in Atara Biotherapeutics during the 3rd quarter valued at about $45,000. Finally, Two Sigma Investments LP bought a new stake in shares of Atara Biotherapeutics during the 3rd quarter worth about $45,000.Atara Biotherapeutics Stock Performance
Shares of ATRA stock opened at $4.72 on Wednesday. The company has a market capitalization of $447.83 million, a P/E ratio of -1.91 and a beta of 1.08. The stock has a 50 day moving average price of $3.86 and a two-hundred day moving average price of $4.10. Atara Biotherapeutics has a fifty-two week low of $2.83 and a fifty-two week high of $16.35.
Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) last released its quarterly earnings data on Tuesday, November 8th. The biotechnology company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.04). The business had revenue of $4.46 million for the quarter, compared to analysts' expectations of $4.37 million. Atara Biotherapeutics had a negative net margin of 348.49% and a negative return on equity of 125.38%. As a group, equities analysts predict that Atara Biotherapeutics will post -2.07 earnings per share for the current year.
About Atara Biotherapeutics
(Get Rating)
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Stories
- Get a free copy of the StockNews.com research report on Atara Biotherapeutics (ATRA)
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Can Coty Stock Emerge in 2023 With Upside
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
- Insiders Buy Archer Aviation, Is This Stock About To Take Off?
- Intuit Is About To Make a Move, But Which Way?
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.